Skip to main content

Table 1 Baseline characteristics

From: Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

Age (years) 53.2 ± 2.6
Gender (male/female) 13/2
Body mass index (kg/m2) 27.1 ± 1.5
Duration of diabetes (years) 7.0 ± 1.0
Diabetes complication  
 Neuropathy 9 (60.0)
 Retinopathy 2 (13.3)
 Nephropathy 0 (0.0)
Diabetes therapy  
 Diet only 2 (13.3)
 Sulfonylurea 12 (80.0)
 Pioglitazone 0 (0.0)
 Metformin 3 (20.0)
Other treatments  
 Lipid-lowering drugs 4 (26.7)
 Antihypertensive drugs 5 (48.8)
Current smokers 9 (60.0)
Cardiovascular disease 2 (13.3)
Systolic blood pressure (mmHg) 127.4 ± 4.3
Diastolic blood pressure (mmHg) 80.6 ± 3.3
LDL-C (mg/dL) 119.5 ± 9.3
HDL-C (mg/dL) 45.7 ± 3.5
Triglycerides (mg/dL) 153.0 ± 9.5
HbA1c (%) 9.5 ± 0.4
Fasting plasma glucose (mg/dL) 153.0 ± 9.5
Immunoreactive insulin (μU/mL) 7.4 ± 1.1
HOMA-IR 2.8 ± 0.5
HOMA-β 32.2 ± 5.7
C-peptide in urine (μg/day) 101.2 ± 18.8
L_RHI 0.54 ± 0.04
  1. Data are mean ± SE, n, or n (%). n = 15.
  2. Abbreviations: LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, HbA1c hemoglobin A1c, HOMA-IR homeostasis model assessment as an index of insulin resistance, HOMA-β homeostasis model assessment beta cell function, L_RHI the natural logarithmic scaled reactive hyperemia index.